George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Revised Non-Executive Director Compensation

23 Dec 2015 13:00

RNS Number : 0601K
Phorm Corporation Limited
23 December 2015
 

23 December 2015

 

Phorm Corporation Limited

("Phorm" or the "Company")

Issue of Equity in respect of Revised Compensation Arrangements for Non-Executive Directors

Phorm (AIM: PHRM), a leading advertising-technology company and first party data platform provider, announces that, on 22 December 2015, it approved a revised compensation scheme for certain Non-Executive Directors of the Company.

The Executive Directors of the Company have reviewed the compensation arrangements for the Company's Non-Executive Directors and undertaken a benchmarking exercise against the median average compensation paid by comparable quoted companies further to PricewaterhouseCoopers International Limited's 2015 report on UK non-executive director compensation. The Executive Directors have agreed that, save for Mr Lin Jieyuan, each of the Company's Non-Executive Directors shall receive compensation of £40,000 per annum. In order to more closely align the Non-Executive Directors' interests with those of the Company and its shareholders and to minimise the group's cash burn rate, it has also been agreed that an element of their compensation packages will be share based.

However, the Board is cognisant that the UK Corporate Governance Code does not advocate the issue of share options to non-executive directors and, accordingly, it has been agreed that, save for Mr Lin Jieyuan, annual compensation for each of the Company's Non-Executive Directors will comprise a cash payment of £20,000 and the issue of ordinary shares to the value of £20,000, which will be subject to a lock-in period, restricting their sale for a period of one year from their date of issue. Phorm's existing Non-Executive Directors have not received any compensation payments since their respective dates of appointment to the Board, such that the aforementioned revised compensation arrangements will be backdated pro rata to their respective dates of appointment.

Accordingly, a total of 1,589,041 new ordinary shares (the "Fee Shares"), representing approximately 0.16 per cent. of the Company's enlarged share capital, will be issued to the Non-Executive Directors to satisfy the amounts due to them for the period from their respective dates of appointment to 31 December 2015 at a price of 3.5 pence per share, as set out below:

Non-Executive Director

Number of Fee Shares

Total Resultant Holding of Ordinary Shares

% of Enlarged Issued Share Capital

Johannes Minho Roth*

823,483

84,657,090

8.61%

Lex Fenwick

479,061

479,061

0.05%

Michael Alkin

286,497

286,497

0.03%

Total:

1,589,041

85,422,648

8.69%

 

* - total resultant holding includes 83,833,607 ordinary shares held by FiveT Investment Management Limited, a company associated with Mr Roth as he is the founding Director, Chief Executive Officer and major shareholder of FiveT Investment Management Limited's parent company, FiveT Capital Holding AG.

Application will be made to the London Stock Exchange plc for the Fee Shares to be admitted to trading on AIM. It is expected that admission of the Fee Shares will become effective and that dealings in the Fee Shares will commence on AIM at 8.00 a.m. on 31 December 2015.

Following admission, the total issued ordinary share capital of the Company will comprise 983,268,816 ordinary shares. The Fee Shares will be fully paid and will rank pari passu in all respects with the Company's existing ordinary shares.

 

-Ends-

For further information please contact: 

Phorm Corporation Limited

Timothy Smith (Chief Executive Officer) +44 (0) 20 3397 6001

 

Mirabaud Securities LLP (Broker) +44 (0) 20 7321 2508

Jason Woollard 

Peter Krens

 

Strand Hanson Limited (Nominated Adviser) +44 (0) 20 7409 3494

James Harris Matthew Chandler James Dance

 

About Phorm:

Phorm is a leading advertising-technology and first party data platform provider that enables brands and publishers to address online users with personalised content and advertising. Phorm's innovative platform delivers a more interesting online experience for the user and addressable campaign results for marketers. For more information, please visit: www.phorm.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSTJBTTMBITBMA
Date   Source Headline
19th Jun 20127:00 amRNSAGM Statement
1st Jun 20127:00 amRNSIntention to Re-Domicile
1st Jun 20127:00 amRNS£20m equity fundraising into Phorm China
22nd May 20127:00 amRNSPhorm Announces AGM Notice & Proposed Board Change
21st Mar 20127:00 amRNSAppointment of Nominated Adviser and Joint Broker
5th Mar 20127:00 amRNSTransfer of Shares
1st Mar 20127:00 amRNSTransfer of Shares
28th Dec 20117:00 amRNSDirector Dealing
12th Dec 201110:10 amRNSTransfer of Shares
7th Dec 201110:19 amRNSTransfer of Shares
2nd Dec 20112:02 pmRNSTR-1: Notification of Major Interest in Shares
2nd Dec 201112:16 pmRNSTransfer of Shares
11th Nov 20117:30 amRNSIssue of Equity
4th Nov 20117:30 amRNSIssue of Equity
21st Oct 20113:28 pmRNSIssue of Equity
20th Oct 20114:14 pmRNSTransfer of Shares
7th Oct 20112:00 pmRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results for Six Months Ended 30 June 2011
28th Sep 20117:00 amRNSProduct Launch
30th Jun 20117:00 amRNSAnnual Financial Report
8th Apr 201112:00 pmRNSBlock Admission Return
30th Mar 20117:00 amRNSTR-1: Notification of Major Interest in Shares
22nd Mar 20117:00 amRNSPlacing and operating update
2nd Mar 201112:00 pmRNSTransfer of Shares
1st Feb 201110:14 amRNSResult of AGM
6th Jan 20117:15 amRNSOption Grant and Modification
6th Jan 20117:05 amRNSAdvisory Board Appointment - Juan Villalonga
24th Dec 20108:11 amRNSNotice of AGM
17th Dec 20109:11 amRNSIssue of convertible secured loan notes
8th Oct 20105:25 pmRNSBlock Admission Return
30th Sep 20107:00 amRNSInterim results
22nd Sep 20107:00 amRNSUpdate on Commercial Deployment in Brazil
17th Aug 20103:42 pmRNSCorrection re Share Transfer
16th Aug 20103:58 pmRNSShare Transfer
16th Aug 20108:50 amRNSDirectorate Change
30th Jul 20101:00 pmRNSTransfer of Shares
23rd Jul 201011:17 amRNSDirectorate Change
16th Jul 20104:25 pmRNSTransfer of Shares
9th Jul 20107:00 amRNSTransfer of Shares
7th Jul 20104:55 pmRNSDirector/PDMR Shareholding
7th Jul 20102:19 pmRNSPlacing of Shares
30th Jun 20102:17 pmRNSAnnual Report & Accounts Notification
30th Jun 20107:00 amRNSPreliminary Results
28th Jun 20107:00 amRNSNotification of results
8th Jun 20102:05 pmRNSChange in name of Nominated Adviser
30th Apr 20101:08 pmRNSGrant of options
9th Apr 20105:25 pmRNSBlock Admission Return
26th Mar 20107:00 amRNSCommercial Deployment in Brazil
28th Jan 20104:37 pmRNSNotification of Major Interest in Shares
11th Jan 20104:28 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.